[go: up one dir, main page]

BR0212556A - interleucina-12 como um adjuvante de vacina veterinária - Google Patents

interleucina-12 como um adjuvante de vacina veterinária

Info

Publication number
BR0212556A
BR0212556A BRPI0212556-0A BR0212556A BR0212556A BR 0212556 A BR0212556 A BR 0212556A BR 0212556 A BR0212556 A BR 0212556A BR 0212556 A BR0212556 A BR 0212556A
Authority
BR
Brazil
Prior art keywords
composition
vaccine
immunogenicity
amount
veterinary vaccine
Prior art date
Application number
BRPI0212556-0A
Other languages
English (en)
Inventor
Hsien-Jue Chu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0212556A publication Critical patent/BR0212556A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INTERLEUCINA-12 COMO UM ADJUVANTE DE VACINA VETERINáRIA". A presente invenção refere-se a um composição para aumentar a imunogenicidade de uma vacina veterinária, que compreende uma quantidade farmacologicamente eficaz de um imunomodulador e um imunoadjuvante. Adicionalmente, a divulgação descreve uma composição de vacina, compreendendo uma quantidade de imunização eficaz de um antígeno, um imunomodulador, um imunoadjuvante e um veículo farmaceuticamente aceitável. As composições podem opcionalmente conter conservantes ou adjuvantes secundários, convencionais. A divulgação também descreve um método único para realçar ou acelerar a imunogenicidade de antígenos fracos, imunossupressores ou marginalmente seguros administrando-se a uma espécie aviária ou mamífera uma quantidade farmacologicamente eficaz da composição aumentada da imunogenicidade supra citada ou uma quantidade de imunização, eficaz da composição de vacina supracitada.
BRPI0212556-0A 2001-09-17 2002-09-13 interleucina-12 como um adjuvante de vacina veterinária BR0212556A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32284001P 2001-09-17 2001-09-17
US10/243,075 US20030129161A1 (en) 2001-09-17 2002-09-12 Interleukin-12 as a veterinary vaccine adjuvant
PCT/US2002/029229 WO2003024354A2 (en) 2001-09-17 2002-09-13 Interleukin-12 as a veterinary vaccine adjuvant

Publications (1)

Publication Number Publication Date
BR0212556A true BR0212556A (pt) 2007-04-17

Family

ID=26935571

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212556-0A BR0212556A (pt) 2001-09-17 2002-09-13 interleucina-12 como um adjuvante de vacina veterinária

Country Status (14)

Country Link
US (2) US20030129161A1 (pt)
EP (1) EP1427349A4 (pt)
JP (1) JP2005520786A (pt)
KR (1) KR20040044942A (pt)
CN (1) CN1555271A (pt)
BR (1) BR0212556A (pt)
CA (1) CA2457563A1 (pt)
HR (1) HRP20040282A2 (pt)
HU (1) HUP0500238A3 (pt)
MX (1) MXPA04002490A (pt)
NZ (1) NZ531526A (pt)
PL (1) PL374123A1 (pt)
WO (1) WO2003024354A2 (pt)
YU (1) YU24004A (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7347996B1 (en) 2002-06-26 2008-03-25 Intevert International B.V. Avian cytokines, such as IL-12, comprising a p40 and/or p35 subunit and vaccines
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
EP1708742A4 (en) * 2003-12-05 2008-11-05 Becton Dickinson Co METHOD FOR IMPROVING THE IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND USEFUL LINKS THEREFOR
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
KR100517114B1 (ko) * 2005-02-25 2005-09-27 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 면역보강제 조성물
ES2485316T3 (es) * 2005-09-01 2014-08-13 Celgene Corporation Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas
US7682619B2 (en) * 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
PT2762163T (pt) 2006-12-27 2018-02-22 Zoetis Services Llc Métodos de administração de vacina
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
US8501190B2 (en) * 2007-06-22 2013-08-06 The University Of Guelph Vaccine against Clostridium perfringens
FR2922767B1 (fr) * 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
UA98812C2 (ru) * 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
US8273122B2 (en) 2008-06-23 2012-09-25 Abbott Medical Optics Inc. Pre-loaded IOL insertion system
EP2501718B1 (en) * 2009-11-20 2016-07-27 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
JP6267510B2 (ja) * 2010-05-18 2018-01-24 ニューメディシンズ，インコーポレーテッド 造血を増強するためのｉｌ−１２製剤
CN102908613A (zh) * 2011-08-04 2013-02-06 广州格拉姆生物科技有限公司 一种猪用免疫增强剂il-12b(p40)及其制备方法
US9651546B2 (en) 2012-10-11 2017-05-16 Abaxis, Inc. Peptides, devices, and methods for the detection of ehrlichia antibodies
CN103028114A (zh) * 2012-12-28 2013-04-10 贵州大学 一种核酸疫苗、核酸疫苗免疫佐剂及制备方法
US9442112B2 (en) 2014-04-04 2016-09-13 Abaxis, Inc. Compositions and methods for identifying Ehrlichia species
CN104857511B (zh) * 2015-02-13 2018-03-30 浙江大学 含人参皂甙的疫苗稀释剂
KR102116528B1 (ko) 2015-09-09 2020-05-28 칭화 유니버시티 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US5047238A (en) * 1983-06-15 1991-09-10 American Home Products Corporation Adjuvants for vaccines
US5503841A (en) * 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4894333A (en) * 1987-05-28 1990-01-16 Immunex Corporation Bovine interleukin-1α
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE365049T1 (de) * 1994-05-10 2007-07-15 Wyeth Corp Abgeänderter, verbesserter brsv lebend- impfstoff
ATE322289T1 (de) * 1994-10-05 2006-04-15 Univ Vanderbilt Interleukin-12 als adjuvans für paramyoxviridae impfstoffe
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
US5665347A (en) * 1995-02-02 1997-09-09 Genetics Institute IL-12 inhibition of B1 cell activity
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5972350A (en) * 1996-05-06 1999-10-26 Bayer Corporation Feline vaccines containing Chlamydia psittaci and method for making the same
JP3737519B2 (ja) * 1996-05-31 2006-01-18 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 百日咳菌ワクチン用アジュバントとしてのｉｌ―１２
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
JP2002502883A (ja) * 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および呼吸合法体ウイルス抗原を含んで成るワクチン
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
US6375944B1 (en) * 1998-09-25 2002-04-23 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the immunostimulatory effect of interleukin-12
US6458942B1 (en) * 1998-11-30 2002-10-01 Research Development Foundation 28-kDa immunoreactive protein gene of Ehrlichia canis and uses thereof
DE50010240D1 (de) * 1999-07-08 2005-06-09 Mologen Forschungs Entwicklung Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze

Also Published As

Publication number Publication date
NZ531526A (en) 2007-05-31
MXPA04002490A (es) 2004-05-31
WO2003024354A3 (en) 2004-02-05
HRP20040282A2 (en) 2004-08-31
KR20040044942A (ko) 2004-05-31
US20030129161A1 (en) 2003-07-10
HUP0500238A2 (hu) 2005-05-30
WO2003024354A2 (en) 2003-03-27
JP2005520786A (ja) 2005-07-14
US20080003201A1 (en) 2008-01-03
PL374123A1 (en) 2005-10-03
EP1427349A2 (en) 2004-06-16
YU24004A (sh) 2006-08-17
EP1427349A4 (en) 2006-01-11
HUP0500238A3 (en) 2009-01-28
CA2457563A1 (en) 2003-03-27
CN1555271A (zh) 2004-12-15

Similar Documents

Publication Publication Date Title
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HU227613B1 (en) Vaccine composition
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
BRPI9912177B8 (pt) epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptídeo sintéticos, imunógenos de peptídeo e método para a produção dos mesmos
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
WO2003003941A3 (en) One dose vaccination with mycoplasma hyopneumoniae
ES2195169T3 (es) Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion.
WO2004026024B1 (en) Vaccine compositions and adjuvant
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
ES2140837T3 (es) Adyuvante a base de saponina de madera de panama y formulacion de vacuna que lo contiene.
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
HK1072264A1 (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
BR9907885A (pt) Composição de vacina, processo para fazer surgir uma resposta imune a um antìgeno de vìrus sincicial respiratório, e, composição imunogênica
WO2003040163B1 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.